Moderna Sets November 6 Date for Q3 2026 Earnings Call
Moderna plans to hold a live conference call and webcast on November 6, 2026, to discuss its third-quarter 2026 financial results and provide a corporate update. The webcast will be accessible through the investors section of the company's website, with an archived version available about two hours after the call and accessible for one year. Moderna describes itself as an mRNA medicine company working on vaccines and therapeutics for infectious diseases, cancer, rare diseases, and other conditions.
Moderna, a Cambridge, Massachusetts-based company traded on Nasdaq under MRNA, will hold its quarterly investor update at 8 a.m. Eastern on Friday, November 6, 2026. The session will cover third-quarter 2026 results and a corporate update.
Investors can join through a live webcast listed in the company’s investor events area. An archived version is expected about two hours after the call and will remain available for one year. Moderna develops messenger RNA-based vaccines and treatments for infectious diseases, cancer, rare diseases, and other conditions.
Moderna’s scheduled earnings call may matter most to investors, patients, and public-health observers because it offers a routine checkpoint on the company’s mRNA pipeline and finances. Clear updates could shape confidence in future vaccines and treatments, while limited news may leave questions about timelines and access. For patients and providers, any signals about late-stage programs or commercialization could influence expectations, though the call itself is unlikely to change care directly.